A detailed history of Virtus Investment Advisers, Inc. transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Virtus Investment Advisers, Inc. holds 61,027 shares of AUTL stock, worth $146,464. This represents 0.03% of its overall portfolio holdings.

Number of Shares
61,027
Holding current value
$146,464
% of portfolio
0.03%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 14, 2025

BUY
$1.55 - $2.68 $94,591 - $163,552
61,027 New
61,027 $94,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $218M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Virtus Investment Advisers, Inc. Portfolio

Follow Virtus Investment Advisers, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus Investment Advisers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Virtus Investment Advisers, Inc. with notifications on news.